Investors in the company have been let down time and again. Some factors for the continued weakness in shares include: A poor acquisition, whereby the company acquired a portfolio of generic drugs from Teva and Allergan for $586 million, only to then take an impairment charge of $285.2 million after failing to calculate the extent of the price reductions it would have to make on the products it acquired to retain key clients.